| |
CME/CE Symposia
Upcoming
CME Seminar During the San Antonio Breast Cancer Symposium |
 |
|
This symposium will address areas of debate in the treatment of MBC. World-renowned thought leaders will present their most intriguing cases from recent years. The intent is to highlight disparities in practice patterns relating to the treatment of MBC, particularly as they relate to drug sequencing. In addition, as new treatment choices emerge in the metastatic setting, adjuvant treatment selection becomes increasingly critical as we begin to establish a breast cancer continuum of care.
:: Learn More
|
|
Upcoming Regional CME Meetings for Physicians |
 |
|
IMER is pleased to offer your institution the opportunity to build a
customized CME grand rounds program using one or more of the following
learning modules:
• Adjuvant Therapy
• Metastatic Disease With Potentially Curative Intent
• Metastatic Disease With Palliative Intent
Each module is 30 minutes in length and is designated for 0.5 CME credits.
In building your grand rounds program, you may choose to incorporate one,
two, or all three modules—for an educational activity that is up to 1.5
hours in length and designated for 1.5 CME credits. Discussions will be
moderated by nationally recognized CRC thought leaders: A surgical
oncologist and a medical oncologist will present the modules on adjuvant therapy and metastatic
disease with curative intent and a medical oncologist will present the
module on metastatic disease with palliative intent.
:: Learn More
|
|
 |
|
It is estimated that more than 50,000 women will develop recurrent or metastatic breast cancer in 2008. Several paradigm shifts in treatment approaches have occurred in recent years as new therapeutic targets have been identified and agents developed to exploit them. This program will provide an overview of the current understanding of these targets and include a discussion of targets that remain under investigation. A breast oncology thought leader will discuss optimization of patient outcomes by integrating novel chemotherapeutic and biologic therapies into treatment. A list of ongoing and accruing clinical trials that may be options for your patients will also be outlined. Attendees are encouraged to bring challenging cases and questions for expert discussion. The program will conclude with a question-and-answer session.
:: Learn More
|
|
| |
|
|
|
Upcoming Regional CE Meetings for Oncology Nurses |
 |
|
Epothilone chemotherapy has recently been approved by the FDA for the treatment of metastatic breast cancer. In this regional CE dinner program, breast cancer nurse experts will address issues pertaining to the use of these agents in clinical practice. An overview of epothilones and their ability to overcome multidrug resistance will be described using 3-D video animation. There will also be a review of the mechanism of action of epothilone chemotherapy and a discussion of administration guidelines. The latter part of the presentation will focus on concerns specific to oncology nurses.
:: Learn More
|
|
 |
|
Patients with cancer are at risk for numerous disease- and treatmen-trelated complications that, if not addressed appropriately, can be life threatening, including TLS and VTE. Prophylaxis and management of such complications are primary responsibilities of oncology nurses; however, clinical presentation may vary between the acute care and ambulatory settings. To support oncology nurse attendees’ efforts to provide individualized patient evaluation and treatment planning, casebased scenarios depicting assessment, prophylaxis, and management strategies for patients with TLS and VTE specific to acute care and ambulatory settings, will be presented. Following the case studies, each table of participants will collaborate to address a list of questions relating to the management of the case, before sharing their analysis with the remaining program attendees.
:: Learn More
|
|
 |
|
The treatment paradigm of non-small cell lung cancer (NSCLC) has shifted in recent years. The inclusion of novel chemotherapeutic agents and targeted therapies into the multimodality approach has resulted in improved patient outcomes. However, the severity and duration of side effects associated with these agents can affect quality of life as well as efficacy of treatment. It is often necessary to adjust treatment schedules, sequences, doses, and number of cycles to alleviate adverse events. Oncology nurses and advanced practice oncology nurses play a critical role in ensuring the optimal delivery of these agents. During this interactive, educational roundtable discussion, a lung cancer oncology nurse key opinion leader will review current treatment options for NSCLC.
:: Learn More
|
|
 |
|
Numerous cancer therapies are associated with HSRs. These infusion-related reactions can range in severity from mild flushing and itching, to anaphylaxis, and in rare cases, death. The accurate identification of the signs and symptoms of HSRs can directly affect treatment decisions. If patients at high risk for experiencing a second reaction can be safely rechallenged, discontinuation of an effective agent may be avoided. It is imperative that oncology nurses are aware of the potential for HSRs when administering therapeutic agents and have protocols in place to prevent and manage these reactions in order to minimize their effects on future treatment.
:: Learn More
|
|
 |
|
Epigenetic silencing of genes that function to suppress carcinogenesis caused by aberrant DNA methylation is one of the mechanisms believed to play a role in the pathogenesis of MDS. Preclinical and clinical research has shown that these epigenetic alterations can be reversed with the use of novel hypomethylating agents. The introduction of such agents has led to a paradigm shift in the treatment of MDS. This nursecentric workshop will comprise three mini-modules addressing diagnostic evaluation, treatment planning, and clinical management of MDS.
:: Learn More
|
|
 |
|
The program will provide an overview of MCL, including
disease pathophysiology, diagnostic work-up, and
current therapeutic options in the front-line, relapsed,
and salvage settings. Novel agents used in the
treatment of MCL will be introduced and their
mechanisms of action described via 3-D video
animation. In addition, data from recent clinical trials
demonstrating the efficacy of such novel agents will be
reviewed. The program will include a discussion of
strategies for supportive care via case presentations of
patient experiences. Program attendees will receive
clinical tools for use in side-effect assessment and
management, and sample patient education materials
for use in their individual clinical practices.
:: Learn More
:: Register
|
|
 |
|
Head and neck cancers (HNC) are a complex collection of
malignancies. They are differentiated, based on histology and tumor
location and many require unique treatment strategies utilizing
multimodal, comprehensive, and interdisciplinary approaches. Two
consecutive educational programs will provide oncology nurses with a
comprehensive understanding of HNC treatment and patient
management. HNC 101 is an introductory program that will define the
different types of HNC and will include disease etiology, staging and
diagnostics. Several case presentations will illustrate the role of various
treatment modalities, including surgery, induction chemotherapy,
chemoradiotherapy, sequential therapies, and targeted therapies.
Nurses from around the country have been invited to submit patient
cases to be discussed by the expert presenter and attendees. HNC 201
will depict continued follow-up on patient cases from HNC 101, however
the focus will be on nursing management of treatment and disease-related
side effects with emphasis on the multidisciplinary approach to
care along the treatment trajectory.
:: Learn More
|
|
 |
|
IMER has now posted answers to the questions posed by the Webcast audience that were unable to be answered during the live program.
Day 1 of this first-of-its-kind conference for APNs and oncology nurses will provide a comprehensive overview of the clinical research landscape of hematologic malignancies. Topics will include chronic myeloid leukemia, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, multiple myeloma, and myelodysplastic syndrome. Day 2 of this conference for APNs and oncology nurses will highlight current trends in the treatment of solid tumors and the clinical application of recent research development.
:: Learn More
|
|
|
|
Login to Register
New user? | Forgot Password?
- ONLINE CE
- Anemia
- Bone Metastases
- Breast Cancer
- Cancer Pain Management
- Colorectal Cancer
- Fertility
- Geroncology
- Non Hodgkin's Lymphomas
- Head and Neck Cancer
- Hematology
- Lung Cancer
- Renal Cell Carcinoma
- Symptom Management
- Targeted Therapies
|
|
